TNFSF10: A Potential Drug Target and Biomarker for Apoptosis (G8743)

Target Name: TNFSF10

NCBI ID: G8743

TNFSF10

TNFSF10: A Potential Drug Target and Biomarker for Apoptosis

Tumor necrosis factor-related apoptosis-inducing ligand (TNF-related apoptosis-inducing ligand, TNFSF10) is a protein that plays a critical role in the regulation of cell apoptosis. It is a member of the tumor necrosis factor (TNF) family, which consists of several pro-inflammatory cytokines that play a crucial role in the development and progression of cancer. TNFSF10 is expressed in a variety of tissues and cells, including immune cells, epithelial cells, and neural cells. Its unique structure and function make it an attractive drug target and biomarker for the development of new treatments for cancer.

The TNFSF10 signaling pathway

TNF-related apoptosis-inducing ligand (TNF-AL) is a cytokine that regulates cell apoptosis by activating and inhibiting various signaling pathways. The most well-studied TNF-AL is TNFSF10, which is composed of two main chains: a long chain fragment (L) and a short chain fragment (S). The L chain consists of a unique N-terminal domain, which is involved in the formation of a complex with the transcription factor, p53, and the downstream adapter protein, p16INK4a. The S chain consists of a variable region and a C-terminal domain.

The L chain of TNFSF10 is responsible for the formation of the DNA-binding domain, which is critical for the regulation of apoptosis. This domain is known as the N-terminal domain and consists of a critical region that interacts with p53 and p16INK4a. The N-terminal domain is involved in the formation of a complex with these transcription factors, which allows for the regulation of apoptosis by TNFSF10.

The S chain of TNFSF10 is responsible for the regulation of apoptosis by affecting various cellular processes, including cell adhesion, migration, and the production of matrix-derived extracellular matrix (ECM) proteins. The S chain is involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in tumors.

TNF-ALs and cancer

TNF-ALs have been shown to play a critical role in the development and progression of cancer. They promote the formation of cancer stem cells (CSCs), which are cells that have the ability to self-renew and differentiate into any cell type in the body. CSCs are a vital component of cancer growth and have been shown to play a critical role in the development of drug-resistant and aggressive tumors.

TNF-ALs have also been shown to promote the formation of immune-evading tumor cells (T-LoC), which are cancer cells that are able to evade the immune system and continue to promote cancer growth. T-LoC have been shown to be particularly resistant to chemotherapy and have a high risk of metastasis.

TNF-ALs as drug targets

TNF-ALs have been shown to be potential drug targets for cancer treatment. Several studies have shown that inhibiting the activity of TNFSF10 can lead to the death of cancer cells, including CSCs and T-LoC. Additionally, inhibiting the activity of TNFSF10 has been shown to improve the efficacy of chemotherapy in various cancers.

One of the potential strategies for targeting TNFSF10 is the use of small molecules, such as inhibitors of the activity of the N-terminal domain. These inhibitors have been shown to be effective in inhibiting the activity of TNFSF10 and have been shown to have potential as a new treatment for cancer.

Another strategy for targeting TNFSF10 is the use of monoclonal antibodies (mAbs), which are antibodies that recognize and selectively bind to a specific protein. mAbs have been shown to be effective in targeting TNFSF10 and have been shown to have potential as a new treatment for cancer.

TNF

Protein Name: TNF Superfamily Member 10

Functions: Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed:26457518, PubMed:10549288). Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis

The "TNFSF10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNFSF10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets